Interchangeable Biosimilar Approved Without Switching Data; Cimerli To Compete With Lucentis

 
• By Sue Sutter
Railroad tracks crossing
Coherus avoided having to conduct a study in which patients switched back and forth between Cimerli and the reference product Lucentis. • Source: Shutterstock

More from Approvals

More from Product Reviews